The Viennese company Marinomed Biotech AG has been in the portfolio of the aws Mittelstandsfonds since October 2015. The company specializes in the development and distribution of innovative therapies for allergy, respiratory and eye diseases.
· Launch of new allergen-blocking nasal spray in Austria for the treatment of hay fever complements existing OTC product portfolio
· Partner M8 Pharmaceuticals launches Carragelose nasal spray for the treatment of viral respiratory infections in Mexico
· Further value maximization and revenue potential for Carragelose asset
The full press release is available here: https://lnkd.in/dk5zfAgM